Red Star Capital Bureau reported on June 3 that a recent online notice stated that food containing the so-called "non-old medicine" NMN will no longer be sold in China through cross-border e-commerce platforms from June 1. In response, Hongxing Capital Bureau contacted a number of listed companies and e-commerce platform stores for verification. Many companies and stores responded that they had not received the notice, while an e-commerce store said that they had received the relevant notice in the last two days.

NMN is called "β-nicotinamide mononucleotide". Anti-aging, immortality and so on were once the marketing pronouns of NMN products. The price of NMN was high in the early days of its launch, which caused controversy because it sold for tens of thousands of yuan a bottle on the e-commerce platform. However, NMN product prices have fallen in recent years as a number of research firms have entered the market.

red star capital bureau incomplete statistics, including huaxi biological (688363.SH), tei pharmaceutical (002728.SZ), jindawei (002626.SZ), yaben chemical (300261.SZ) and many other listed companies have NMN-related business layout.

regarding the statement that "NMN food from the" non-old drug "should no longer be sold in China through cross-border e-commerce platforms", on the afternoon of June 3, tei pharmaceutical replied to the red star capital bureau that it had not yet received the relevant notice. For the NMN layout, the company currently only wholly-owned subsidiaries Xinning Pharmaceutical and Taishan Chemical to its project and carry out process research, related products are still in the early stages of research and development.

according to the financial association news agency, Yaben chemical responded that the company has noticed the relevant rumors a few days ago and is in the process of verification. The company has NMN-related dietary supplement products sold domestically through imports, for extreme cases, the relevant departments have a response plan. Jindawei said that the company has noticed relevant rumors and discussions. The relevant indicators of the company's NMN-related products have not yet reached the standards that need to be disclosed, and the company will respond or disclose relevant information if necessary.

red star capital bureau noted that jindawei's 2023 annual report mentioned that the company's health food raw material products include NMN series products, and the end products are mainly sold through cross-border e-commerce and duty-free shops in China. the actual production capacity of NMN series is 500 tons.

According to a report by Zhongxin Jingwei, the staff of Erkang Pharmaceutical's Secretary Office said that the company mainly produces raw and auxiliary materials and has NMN approval, but it has not been produced at present. The company's e-commerce business accounts for a very small percentage of overall revenue. If the notice is true, the impact on the company's current production and operation may need to be comprehensively evaluated, but from the perspective of the company as a whole, the proportion of product sales, and various business sectors, the impact is minimal.

in addition to listed companies, red star capital bureau also contacted a number of business platform shops for verification. Jingdong platform, including GLGFAS health products overseas flagship store, SLEKAN overseas flagship store, including a number of store customer service said, did not receive the relevant notice, do not know the relevant notice. Taobao Tmall platform, LIFEGENE overseas flagship stores and other store customer service also hold the same statement.

Screenshot from e-commerce platform

the customer service of a store called "Meiji Medicine" said that it had indeed received relevant notices in the last two days. Specifically: "Foods containing NMN ingredients are prohibited from being sold, and foods containing NMN ingredients such as the United States, Australia, Germany, Switzerland, and the United Kingdom are not allowed to be sold on cross-border e-commerce platforms." When the Red Star Capital Bureau asked whether it would affect the sales of store products, the customer service said that the origin of the products was not in the notice.

according to the financial association news agency, in January 2021, the State Administration of market supervision issued a letter on investigating illegal operation of "non-old drugs", pointing out that in China, NMN has not obtained licenses for drugs, health food, food additives and new food raw materials, that is, NMN cannot be produced and operated as food in China. In January 2022, the General Administration of market supervision responded to the motion of deputies to the National People's Congress, the attitude towards NMN is still "the positioning and safety of NMN as a food raw material is not clear"; In May 2023, the official website of the Health and Health Commission issued a new batch of new food additive varieties without administrative license, and NMN was included in the new list.